Barclays Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $165.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective lifted by Barclays from $160.00 to $165.00 in a report published on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other equities research analysts have also issued reports on NBIX. Wedbush reissued an “outperform” rating and set a $148.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, Raymond James reissued an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $166.29.

Neurocrine Biosciences Stock Down 0.3 %

Shares of Neurocrine Biosciences stock opened at $136.53 on Monday. The business has a 50-day moving average price of $124.79 and a 200 day moving average price of $130.60. Neurocrine Biosciences has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The firm has a market cap of $13.82 billion, a P/E ratio of 36.60 and a beta of 0.34.

Insiders Place Their Bets

In related news, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now directly owns 2,507 shares of the company’s stock, valued at $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Institutional Trading of Neurocrine Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fifth Third Bancorp increased its holdings in shares of Neurocrine Biosciences by 14.7% in the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock valued at $99,000 after buying an additional 92 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Neurocrine Biosciences by 1.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock worth $128,639,000 after acquiring an additional 13,069 shares during the last quarter. Burney Co. raised its position in shares of Neurocrine Biosciences by 4.1% during the second quarter. Burney Co. now owns 82,578 shares of the company’s stock worth $11,369,000 after purchasing an additional 3,236 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Neurocrine Biosciences by 41.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 90,018 shares of the company’s stock valued at $12,393,000 after purchasing an additional 26,195 shares during the last quarter. Finally, Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at $30,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.